NDC 64406-019

Byooviz

Ranibizumab-nuna

Byooviz is a Intravitreal Injection, Solution in the Human Prescription Drug category. It is labeled and distributed by Biogen Inc.. The primary component is Ranibizumab.

Product ID64406-019_1c0b50cf-e8c4-45ab-bbb0-4a241c25c062
NDC64406-019
Product TypeHuman Prescription Drug
Proprietary NameByooviz
Generic NameRanibizumab-nuna
Dosage FormInjection, Solution
Route of AdministrationINTRAVITREAL
Marketing Start Date2022-06-01
Marketing CategoryBLA /
Application NumberBLA761202
Labeler NameBIOGEN INC.
Substance NameRANIBIZUMAB
Active Ingredient Strength10 mg/mL
Pharm ClassesVascular Endothelial Growth Factor Inhibitor [EPC], Vascular Endothelial Growth Factor Inhibitors [MoA]
NDC Exclude FlagN
Listing Certified Through2023-12-31

Packaging

NDC 64406-019-01

1 VIAL, SINGLE-DOSE in 1 CARTON (64406-019-01) > .05 mL in 1 VIAL, SINGLE-DOSE (64406-019-07)
Marketing Start Date2022-06-01
NDC Exclude FlagN
Sample Package?N

Drug Details


Trademark Results [Byooviz]

Mark Image

Registration | Serial
Company
Trademark
Application Date
BYOOVIZ
BYOOVIZ
90687009 not registered Live/Pending
Biogen MA Inc.
2021-05-03
BYOOVIZ
BYOOVIZ
90071392 not registered Live/Pending
Biogen MA Inc.
2020-07-24

© 2024 FDA.report
This site is not affiliated with or endorsed by the FDA.